Načítá se...

Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies

BACKGROUND: Troxacitabine is a novel L-nucleoside analogue. Preclinical studies showed improved activity with infusions of at least 3 days compared with bolus regimens, especially at concentrations >20 ng/ml. This phase I study tested the feasibility of achieving a troxacitabine steady-state conc...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Jimeno, A., Messersmith, W. A., Lee, C. K., Ma, W. W., Laheru, D., Donehower, R. C., Baker, S. D., Hidalgo, M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2008
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3557502/
https://ncbi.nlm.nih.gov/pubmed/18245131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdm572
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!